The first real-world outcomes data for nadofaragene firadenovec (Adstiladrin, Ferring Pharmaceuticals) in patients with Bacillus Calmette-GuÉrin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) support the gene therapy’s efficacy and safety, with promising clinical response (CR) rates and a tolerable adverse event (AE) profile.
NMIBC is the most common type of bladder cancer, affecting about 3 in 4 people with the malignancy. BCG, an intravesical